ArticleJournal for immunotherapy of cancer2023

CLDN18.2 and 4-1BB bispecific antibody givastomig exerts antitumor activity through CLDN18.2-expressing tumor-directed T-cell activation.

Jing Gao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.